Dalrada (DFCO). Our 11th and Latest Ten Bagger.
We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we should say,...
Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.
Added to Watch List November 2019 @$0.55.
Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021 @$1.80Cash has Risen From $3.3 Million...
The FDA Cracks Down On Stem Cell Therapy.
Due to a somewhat unexpected crackdown on stem cell treatment centers a couple of weeks ago - we have decided to hold off launching...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
IDMC meets on June 29 for Superiority review.Mino-Lok has no competition.Price target increased to...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
We're up 370% since adding it to the Biotech Stock Review Watch List...
Stocks On The Move!
Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the Alkaline Water...
Discontinuing Coverage on Dalrada (DFCO).
We Are Temporarily Discontinuing Coverage on Dalrada Financial.
Great little company and we're up 400%. But with the market for small caps getting a bit...
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT)...
Old News, But Wow: Starr Foundation Reaffirms Support for Stem Cell Research with $50...
Someone is a Big Believer and Cutting Equally Big Checks!
NEW YORK (April 4, 2019) — The Starr Foundation is continuing its longstanding commitment to...
Stem Cell Play Organicell (BPSR) Screams Higher.
Stock Levitates After Series of Positive Press Releases on Zofrin.
Added to the Watch List in April a little more than a year ago after...